The FDA failed to enforce rules that require drug and device firms to detail the financial interests of outside experts who test experimental treatments before companies file for approval, according to a report from the HHS inspector general. The study is based on 118 new-drug applications that the FDA cleared in 2007. An FDA spokeswoman said the agency does not favor examining clinical investigators' financial conflicts prior to trials because they represent only one source of possible bias.

Related Summaries